Stepping in to supply the market during US shortages of generic Adderall (mixed amphetamine salts), combined with a “more favorable pricing environment” for US generics, have helped to boost Lannett in its financial first quarter ended 30 September, allowing the firm to generate what it described as “better than expected financial results.”
Nevertheless, Lannett’s sales still slid by more than a quarter to $75.1m and the company reported an operating loss of...







